SCHEMBL12713228

SCHEMBL12713228

CCC(CO)Cc1cc(F)ccc1C1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 5/20 0.51
▸ DPP4 P27487 1/20 0.48
▸ ALDH1A1 P00352 2/20 0.45
▸ LMNA P02545 2/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ TRPV3 Q8NET8 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ MAPT P10636 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ CNR1 P21554 1/20 0.42
▸ CNR2 P34972 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12713231 0.90 GPR119 (0.49) GPR119DPP4ALDH1A1LMNACYP3A4
SCHEMBL12713213 0.88 SMN1; SMN2 (0.47) DPP4ALDH1A1LMNASMN1; SMN2TRPV3
SCHEMBL14435978 0.88 GPR119 (0.52) GPR119DPP4ALDH1A1LMNACYP3A4
SCHEMBL12713229 0.85 GPR119 (0.50) GPR119DPP4ALDH1A1LMNACYP3A4
SCHEMBL2338827 0.85 GPR119 (0.52) GPR119DPP4ALDH1A1LMNACYP3A4
SCHEMBL12713227 0.85 GPR119 (0.51) GPR119DPP4ALDH1A1LMNACYP3A4
SCHEMBL17223034 0.79 SMN1; SMN2 (0.52) GPR119ALDH1A1LMNACYP3A4CYP2D6
SCHEMBL20438978 0.79 SMN1; SMN2 (0.59) GPR119ALDH1A1LMNACYP3A4CYP2D6
SCHEMBL3547383 0.78 SMN1; SMN2 (0.53) GPR119ALDH1A1LMNACYP3A4CYP2D6
SCHEMBL13002965 0.77 SMN1; SMN2 (0.44) DPP4ALDH1A1LMNASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110086836-A1 Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2011-04-14 — — US disclosed
US-20110086836-A1 Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2011-04-14 — — US disclosed
EP-2004604-B1 SUBSTITUTED PHENYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS SANTHERA PHARMACEUTICALS CH (CH) 2010-12-01 — — EP disclosed
WO-2007115798-A1 SUBSTITUTED PHENYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2007-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110086836-A1 Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators MC4R, MC5R, MC3R GPR119 7/4885DPP4 71/4885ALDH1A1 2826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback